8 februari 2010
Alternativa Aktiemarknaden har trots påtryckningar från Alligator Bioscience beslutat att ännu inte upphöra med noteringen på Alternativas handelsplats för onoterade aktier. Alligator vill därför åter klargöra att beslutet att inleda handel med Alligator Biosciences aktier skett utan någon som helst medverkan från bolagets sida. Alligator har uppmärksammat Finansinspektionen på den uppkomna situationen.
20 januari 2010
Alternativa aktiemarknadens initiativ
Alternativa aktiemarknaden har i januari 2010 beslutat inleda handel med Alligator Bioscience ABs aktier. Detta har skett utan Alligators medverkan och i strid med bolagets vilja. Alligator har bett Alternativa aktiemarknaden att upphöra med noteringen av bolagets aktier
Januari 11, 2010

Alligator Bioscience´s protein drug candidate ADC-1004 for treatment of ischemia reperfusion (I/R) injury reduced myocardial infarct size in a porcine model

Read more>>
December 2, 2009
Alligator Bioscience Awarded New Patent for its Protein Optimization Technology FIND® in Japan
Read more>>
1 december 2009
Per-Olof Mårtensson lämnar styrelsen
Per-Olof Mårtensson har, efter en lång och framgångsrik karriär inom internationell läkemedels, bioteknik och medicinsk teknisk industri, under de senaste åren valt att stegvis trappa ner sina engagemang och har nu beslutat sig för att lämna styrelsen för Alligator Bioscience AB.  
Read more >>

"We use our FIND®-technology platform to develop innovative protein based drug candidates for unmet medical needs within Inflammation and Cancer

- in collaboration with academic and commercial partners"

- also suitable for antibodies
ADC-1004 Protects Against
Inflammation Injury
Reperfusion injury is a serious complication after e.g. myocardial infarction treated with balloon dilatation. Alligator Bioscience has created a drug candidate, ADC-1004, that is assumed to protect against this reperfusion injury. 
READ MORE ...		  
        
ADC-1001 Second Generation IL-1Ra
Our FIND® technology has proven to be very useful in creating second generation biopharmaceuticals. Alligator Bioscience has made a second generation drug candidate of Anakinra (Kineret®) with increased receptor affinity compared to Anakinra.
READ MORE …
 
 
        
Gun-Britt Fransson, CEO
"The success of biopharmaceuticals has resulted in major pharmaceutical companies committing themselves to protein drug development. Our FIND® technology makes Alligator Bioscience the perfect partner in developing tomorrows therapies meeting patients' and doctors' needs."
    
Bengt Larsson, CMO
“ADC-1004 has the potential to become a standard add-on treatment in any situation where ischemia reperfusion injury is a risk, including acute myocardinal infarction treated with Percutaneous Coronary Intervention, stroke treated with thrombolysis and at transplantation. No treatment is yet available to reduce ischemia reperfusion injury."
    
Eva Dahlen, Head of Discovery
“For a company like Alligator Bioscience it is crucial to maintain a continuous influx of good ideas, a scientifically skilled and creative staff to evaluate and prioritize them, and finally a unique technology platform to optimize and develop them.”

  
Christina Furebring, VP R&D
“We use our FIND® technology to redesign the protein to best suit the specific therapeutic requirements. We are not limited to native proteins or by constrains in conventional protein engineering techniques.”
 
Alligator Bioscience AB :: Scheelevägen 19A :: 223 70 Lund :: Phone: + 46 (0)46 286 4280 :: Fax: + 46 (0)46 286 4290
Copyright © 2008 Alligator Bioscience AB. All rights reserved